{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:41:17Z","timestamp":1793871677952,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41591-018-0140-5","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T09:25:18Z","timestamp":1533806718000},"page":"1579-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":381,"title":["Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent"],"prefix":"10.1038","volume":"24","author":[{"given":"Koki","family":"Fujimori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Otomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Hadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6610-1902","authenticated-orcid":false,"given":"Hideyuki","family":"Saya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"140_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1474-4422(11)70024-2","volume":"10","author":"L Zinman","year":"2011","unstructured":"Zinman, L. & Cudkowicz, M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 10, 481\u2013490 (2011).","journal-title":"Lancet Neurol."},{"key":"140_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen, D. R. et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59\u201362 (1993).","journal-title":"Nature"},{"key":"140_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng1001-166","volume":"29","author":"S Hadano","year":"2001","unstructured":"Hadano, S. et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29, 166\u2013173 (2001).","journal-title":"Nat. Genet."},{"key":"140_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602\u2013611 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"140_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130\u2013133 (2006).","journal-title":"Science"},{"key":"140_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"TJ Kwiatkowski Jr","year":"2009","unstructured":"Kwiatkowski, T. J.Jr et al. Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205\u20131208 (2009).","journal-title":"Science"},{"key":"140_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.1165942","volume":"323","author":"C Vance","year":"2009","unstructured":"Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208\u20131211 (2009).","journal-title":"Science"},{"key":"140_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature08971","volume":"465","author":"H Maruyama","year":"2010","unstructured":"Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223\u2013226 (2010).","journal-title":"Nature"},{"key":"140_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.conb.2011.05.029","volume":"21","author":"S Cruz Da","year":"2011","unstructured":"Da Cruz, S. & Cleveland, D. W. Understanding the role of TDP-43 and FUS\/TLS in ALS and beyond. Curr. Opin. Neurobiol. 21, 904\u2013919 (2011).","journal-title":"Curr. Opin. Neurobiol."},{"key":"140_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.21704","volume":"66","author":"HN Liu","year":"2009","unstructured":"Liu, H. N. et al. Lack of evidence of monomer\/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 66, 75\u201380 (2009).","journal-title":"Ann. Neurol."},{"key":"140_CR11","doi-asserted-by":"publisher","first-page":"e1002214","DOI":"10.1371\/journal.pgen.1002214","volume":"7","author":"E Kabashi","year":"2011","unstructured":"Kabashi, E. et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet. 7, e1002214 (2011).","journal-title":"PLoS Genet."},{"key":"140_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-017-1688-8","volume":"134","author":"S Cruz Da","year":"2017","unstructured":"Da Cruz, S. et al. Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. 134, 97\u2013111 (2017).","journal-title":"Acta Neuropathol."},{"key":"140_CR13","doi-asserted-by":"crossref","first-page":"5.67.61","DOI":"10.1002\/0471141755.ph0567s69","volume":"69","author":"T Philips","year":"2015","unstructured":"Philips, T. & Rothstein, J. D. Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 69, 5.67.61\u201321 (2015).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"140_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF00308955","volume":"79","author":"H Mizusawa","year":"1989","unstructured":"Mizusawa, H. et al. Focal accumulation of phosphorylated neurofilaments within anterior horn cell in familial amyotrophic lateral sclerosis. Acta Neuropathol. 79, 37\u201343 (1989).","journal-title":"Acta Neuropathol."},{"key":"140_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/BF00296370","volume":"81","author":"K Okamoto","year":"1991","unstructured":"Okamoto, K., Hirai, S., Ishiguro, K., Kawarabayashi, T. & Takatama, M. Light and electron microscopic and immunohistochemical observations of the Onuf\u2019s nucleus of amyotrophic lateral sclerosis. Acta Neuropathol. 81, 610\u2013614 (1991).","journal-title":"Acta Neuropathol."},{"key":"140_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"AE Renton","year":"2014","unstructured":"Renton, A. E., Chio, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17\u201323 (2014).","journal-title":"Nat. Neurosci."},{"key":"140_CR17","doi-asserted-by":"publisher","first-page":"757.e713","DOI":"10.1016\/j.neurobiolaging.2010.12.011","volume":"32","author":"A Iida","year":"2011","unstructured":"Iida, A. et al. Replication analysis of SNPs on 9p21.2 and 19p13.3 with amyotrophic lateral sclerosis in East Asians. Neurobiol. Aging 32, 757.e713\u2013754 (2011).","journal-title":"Neurobiol. Aging"},{"key":"140_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747\u2013753 (2009).","journal-title":"Nature"},{"key":"140_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(11)70022-9","volume":"10","author":"VB Mattis","year":"2011","unstructured":"Mattis, V. B. & Svendsen, C. N. Induced pluripotent stem cells: a new revolution for clinical neurology?. Lancet Neurol. 10, 383\u2013394 (2011).","journal-title":"Lancet Neurol."},{"key":"140_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-7-22","volume":"7","author":"H Okano","year":"2014","unstructured":"Okano, H. & Yamanaka, S. iPS cell technologies: significance and applications to CNS regeneration and disease. Mol. Brain 7, 22 (2014).","journal-title":"Mol. Brain"},{"key":"140_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature09342","volume":"467","author":"K Kim","year":"2010","unstructured":"Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285\u2013290 (2010).","journal-title":"Nature"},{"key":"140_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cga.12206","volume":"57","author":"H Okuno","year":"2017","unstructured":"Okuno, H. et al. Changeability of the fully methylated status of the 15q11.2 region in induced pluripotent stem cells derived from a patient with Prader\u2013Willi syndrome. Congenit. Anom. (Kyoto) 57, 96\u2013103 (2017).","journal-title":"Congenit. Anom. (Kyoto)"},{"key":"140_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.stemcr.2016.02.011","volume":"6","author":"N Ichiyanagi","year":"2016","unstructured":"Ichiyanagi, N. et al. Establishment of in vitro FUS-associated familial amyotrophic lateral sclerosis model using human induced pluripotent stem cells. Stem Cell Reports 6, 496\u2013510 (2016).","journal-title":"Stem Cell Reports"},{"key":"140_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.stemcr.2017.09.024","volume":"9","author":"K Fujimori","year":"2017","unstructured":"Fujimori, K. et al. Escape from pluripotency via inhibition of TGF-\u03b2\/BMP and activation of wnt signaling accelerates differentiation and aging in hPSC progeny cells. Stem Cell Reports 9, 1675\u20131691 (2017).","journal-title":"Stem Cell Reports"},{"key":"140_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-016-0267-6","volume":"9","author":"K Fujimori","year":"2016","unstructured":"Fujimori, K. et al. Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines. Mol. Brain 9, 88 (2016).","journal-title":"Mol. Brain"},{"key":"140_CR26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.stemcr.2016.01.010","volume":"6","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto, T. et al. Functional neurons generated from T cell-derived induced pluripotent stem cells for neurological disease modeling. Stem Cell Reports 6, 422\u2013435 (2016).","journal-title":"Stem Cell Reports"},{"key":"140_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nsmb.2053","volume":"18","author":"W Guo","year":"2011","unstructured":"Guo, W. et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Struct. Mol. Biol. 18, 822\u2013830 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"140_CR28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ajhp\/56.3.217","volume":"56","author":"MD Kuzel","year":"1999","unstructured":"Kuzel, M. D. Ropinirole: a dopamine agonist for the treatment of Parkinson\u2019s disease. Am. J. Health Syst. Pharm. 56, 217\u2013224 (1999).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"140_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/jnr.10127","volume":"67","author":"NA Abramova","year":"2002","unstructured":"Abramova, N. A., Cassarino, D. S., Khan, S. M., Painter, T. W. & Bennett, J. PJr.. Inhibition by R(\u2009+\u2009) or S(\u2212) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J. Neurosci. Res. 67, 494\u2013500 (2002).","journal-title":"J. Neurosci. Res."},{"key":"140_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1124\/jpet.105.092312","volume":"316","author":"R Danzeisen","year":"2006","unstructured":"Danzeisen, R. et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J. Pharmacol. Exp. Ther. 316, 189\u2013199 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"140_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2210-10-2","volume":"10","author":"G Ferrari-Toninelli","year":"2010","unstructured":"Ferrari-Toninelli, G., Maccarinelli, G., Uberti, D., Buerger, E. & Memo, M. Mitochondria-targeted antioxidant effects of S(\u2212) and R(+) pramipexole. BMC Pharmacol. 10, 2 (2010).","journal-title":"BMC Pharmacol."},{"key":"140_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1471-4159.2004.02804.x","volume":"91","author":"M Gu","year":"2004","unstructured":"Gu, M. et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075\u20131081 (2004).","journal-title":"J. Neurochem."},{"key":"140_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0006-8993(97)00075-9","volume":"754","author":"VH Sethy","year":"1997","unstructured":"Sethy, V. H., Wu, H., Oostveen, J. A. & Hall, E. D. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754, 181\u2013186 (1997).","journal-title":"Brain Res."},{"key":"140_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1471-4159.1998.71010295.x","volume":"71","author":"DS Cassarino","year":"1998","unstructured":"Cassarino, D. S., Fall, C. P., Smith, T. S. & Bennett, J. P.Jr.. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71, 295\u2013301 (1998).","journal-title":"J. Neurochem."},{"key":"140_CR35","doi-asserted-by":"publisher","first-page":"50\u2013","DOI":"10.1080\/17482960701791234","volume":"9","author":"H Wang","year":"2008","unstructured":"Wang, H. et al. R+\u2009pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph. Lateral Scler. 9, 50\u2013\u201358 (2008).","journal-title":"Amyotroph. Lateral Scler."},{"key":"140_CR36","first-page":"911","volume":"13","author":"BC Cheah","year":"2010","unstructured":"Cheah, B. C. & Kiernan, M. C. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs 13, 911\u2013920 (2010).","journal-title":"IDrugs"},{"key":"140_CR37","first-page":"359","volume":"8","author":"P Corcia","year":"2012","unstructured":"Corcia, P. & Gordon, P. H. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther. Clin. Risk Manag. 8, 359\u2013366 (2012).","journal-title":"Ther. Clin. Risk Manag."},{"key":"140_CR38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","volume":"12","author":"ME Cudkowicz","year":"2013","unstructured":"Cudkowicz, M. E. et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 12, 1059\u20131067 (2013).","journal-title":"Lancet Neurol."},{"key":"140_CR39","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1093\/hmg\/ddr268","volume":"20","author":"A Iida","year":"2011","unstructured":"Iida, A. et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum. Mol. Genet. 20, 3684\u20133692 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"140_CR40","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1136\/jnnp-2013-306020","volume":"84","author":"R Nakamura","year":"2013","unstructured":"Nakamura, R. et al. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. J. Neurol. Neurosurg. Psychiatry 84, 1365\u20131371 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"140_CR41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/jnnp-2015-311541","volume":"87","author":"H Watanabe","year":"2016","unstructured":"Watanabe, H. et al. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J. Neurol. Neurosurg. Psychiatry 87, 851\u2013858 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"140_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","volume":"26","author":"WS Yang","year":"2016","unstructured":"Yang, W. S. & Stockwell, B. R. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165\u2013176 (2016).","journal-title":"Trends Cell Biol."},{"key":"140_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.mam.2011.10.010","volume":"32","author":"Z Radak","year":"2011","unstructured":"Radak, Z., Zhao, Z., Goto, S. & Koltai, E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol. Aspects Med. 32, 305\u2013315 (2011).","journal-title":"Mol. Aspects Med."},{"key":"140_CR44","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.freeradbiomed.2011.06.027","volume":"51","author":"TT Reed","year":"2011","unstructured":"Reed, T. T. Lipid peroxidation and neurodegenerative disease. Free Radic. Biol. Med. 51, 1302\u20131319 (2011).","journal-title":"Free Radic. Biol. Med."},{"key":"140_CR45","first-page":"289","volume":"9","author":"CJ Alves","year":"2015","unstructured":"Alves, C. J. et al. Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Front Cell Neurosci. 9, 289 (2015).","journal-title":"Front Cell Neurosci."},{"key":"140_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mcn.2013.07.007","volume":"56","author":"MF Burkhardt","year":"2013","unstructured":"Burkhardt, M. F. et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell Neurosci. 56, 355\u2013364 (2013).","journal-title":"Mol. Cell Neurosci."},{"key":"140_CR47","doi-asserted-by":"crossref","unstructured":"Imamura, K. et al. The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 9, (2017).","DOI":"10.1126\/scitranslmed.aaf3962"},{"issue":"Suppl 1","key":"140_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/21678421.2013.778548","volume":"14","author":"J Ravits","year":"2013","unstructured":"Ravits, J. et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14 (Suppl 1), 5\u201318 (2013).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"140_CR49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.21147","volume":"61","author":"IR Mackenzie","year":"2007","unstructured":"Mackenzie, I. R. et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 61, 427\u2013434 (2007).","journal-title":"Ann. Neurol."},{"key":"140_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp.65.2.263","volume":"65","author":"GD Borasio","year":"1998","unstructured":"Borasio, G. D. et al. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg. Psychiatry 65, 263\u2013265 (1998).","journal-title":"J Neurol Neurosurg. Psychiatry"},{"key":"140_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0305-0491(98)10160-8","volume":"122","author":"RL Cooper","year":"1999","unstructured":"Cooper, R. L. & Neckameyer, W. S. Dopaminergic modulation of motor neuron activity and neuromuscular function in Drosophila melanogaster. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 122, 199\u2013210 (1999).","journal-title":"Comp. Biochem. Physiol. B Biochem. Mol. Biol."},{"key":"140_CR52","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1111\/j.1460-9568.2007.05870.x","volume":"26","author":"N Yuan","year":"2007","unstructured":"Yuan, N. & Lee, D. Suppression of excitatory cholinergic synaptic transmission by Drosophila dopamine D1-like receptors. Eur. J. Neurosci. 26, 2417\u20132427 (2007).","journal-title":"Eur. J. Neurosci."},{"key":"140_CR53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.devcel.2013.04.012","volume":"25","author":"MM Reimer","year":"2013","unstructured":"Reimer, M. M. et al. Dopamine from the brain promotes spinal motor neuron generation during development and adult regeneration. Dev. Cell 25, 478\u2013491 (2013).","journal-title":"Dev. Cell"},{"key":"140_CR54","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1212\/WNL.62.10.1758","volume":"62","author":"EP Simpson","year":"2004","unstructured":"Simpson, E. P., Henry, Y. K., Henkel, J. S., Smith, R. G. & Appel, S. H. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62, 1758\u20131765 (2004).","journal-title":"Neurology"},{"key":"140_CR55","doi-asserted-by":"publisher","first-page":"28097","DOI":"10.1074\/jbc.M115.680090","volume":"290","author":"L Chen","year":"2015","unstructured":"Chen, L., Hambright, W. S., Na, R. & Ran, Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J. Biol. Chem. 290, 28097\u201328106 (2015).","journal-title":"J. Biol. Chem."},{"key":"140_CR56","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"140_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-5-35","volume":"5","author":"Y Imaizumi","year":"2012","unstructured":"Imaizumi, Y. et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain 5, 35 (2012).","journal-title":"Mol. Brain"},{"key":"140_CR58","doi-asserted-by":"publisher","first-page":"145ra104","DOI":"10.1126\/scitranslmed.3004052","volume":"4","author":"N Egawa","year":"2012","unstructured":"Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104 (2012).","journal-title":"Sci. Transl. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0140-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:56:56Z","timestamp":1684619816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-018-0140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1038\/s41591-018-0140-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"28 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.O. is a paid Scientific Advisory Board Member at SanBio Co., Ltd. and K Pharma Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}